МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ДЛЯ ДЕТЕКЦИИ СА-125 И MISRII - ПОВЕРХНОСТНЫХ МАРКЕРОВ АДЕНОКАРЦИНОМЫ ЯИЧНИКОВ

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019 //CA: a cancer journal for clinicians. - 2019. - Vol. 69. - №. 1. - P. 7-34.

2. Barnholtz-Sloan J.S. et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades //American journal of obstetrics and gynecology. - 2003. - Vol. 189. - №. 4. - P. 1120-1127.

3. Van der Burg M.E., Lammes F.B., Verweij J. CA 125 in ovarian cancer //The Netherlands journal of medicine. - 1992. - Vol. 40. - №. 1-2. - P. 36-51.

4. Bakkum-Gamez J.N. et al. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers //Gynecologic oncology. - 2008. - Vol. 108. - №. 1. - P. 141-148.

5. Estupina P. et al. The anti-tumor efficacy of 3С23К, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells // Oncotarget. - 2017. - Vol. 8. - №. 23. - P. 37061-37079.